VALBIOTIS

VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.

Pipeline

VALBIOTIS accelerates the clinical development of its pipeline in new indications: reducing cardiovascular risk and hepatic steatosis.

Learn more

TOTUM-63

Initiation of the pivotal late stage development phase of TOTUM-63, with Nestlé Health Science

Learn more

VALBIOTIS

VALBIOTIS announces a global strategic partnership with NESTLÉ HEALTH SCIENCE for the development and commercialization of TOTUM-63

Learn more

1 4

S c r o l l

Products

.01

TOTUM-63

Prediabetes, risk condition for Type 2 Diabetes
> Clinical Phase II positive
> Clinical Phase II/III pending

Learn more

.02

TOTUM-070

Mild to moderate hypercholesterolemia, risk factor for cardiovascular diseases
> Clinical Phase II pending

Learn more

.03

TOTUM-448

Non-alcoholic hepatic steatosis, risk condition for NASH
> Clinical Phase II pending

Learn more

.04

TOTUM-854

Elevated blood pressure, a risk factor for cardiovascular diseases
> Clinical Phase II pending

Learn more

Key figures

Patent families filed

All exploitation rights obtained

Employees

> 35

75% in R&D

Listed on the Stock Exchange

2017

Euronext Growth

Our last posts

11.02.2020

Investor meetings – Portzamparc

28.01.2020

Biomed Event

16.10.2019

French Society of Financial Analysts (SFAF)

14.10.2019

European Large & Midcap Event

Voir tous

Learn more

VALBIOTIS

Products

TOTUM-63

TOTUM-070

TOTUM-448

TOTUM-854

Key figures

Patent families filed

Employees

Listed on the Stock Exchange

Our last posts

Investor meetings – Portzamparc

Biomed Event

French Society of Financial Analysts (SFAF)

European Large & Midcap Event

VALBIOTIS© listed on the Stock Exchange

Follow us!